Physician profile
Sanjay Garg
NPI 1891997458
$10,106.33
in general payments reported to CMS, 2019-2025
28 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $238 · 2021: $762 · 2022: $1,351 · 2023: $4,048 · 2024: $1,429 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,720 · Consulting Fee: $2,760 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,719.81 |
| Consulting Fee | $2,760.00 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,339.00 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $1,822.15 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $735.00 | 2019-2025 | |
| Genzyme Corporation | $528.04 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $472.92 | 2022-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $443.12 | 2019-2025 | |
| Horizon Therapeutics Plc | $429.17 | 2019-2023 | Krystexxa |
| Pfizer INC. | $360.76 | 2019-2025 | |
| Janssen Biotech, INC. | $305.75 | 2019-2024 | Simponi Aria, Remicade, Tremfya |
| Lilly USA, LLC | $245.90 | 2019-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $214.11 | 2019-2025 | Benlysta |
| Sanofi-Aventis U.S. LLC | $188.99 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $170.28 | 2022-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $156.57 | 2023-2025 | Idacio |
| Radius Health, INC. | $154.69 | 2020-2025 | Tymlos |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $89.49 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $82.33 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $61.22 | 2022-2023 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $55.08 | 2019-2024 | Orencia |
| Genentech USA, INC. | $54.20 | 2019-2023 | Actemra |
| Organon LLC | $49.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $41.87 | 2021 | |
| Medexus Pharma, INC. | $26.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.78 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $17.73 | 2019 | |
| Sobi, INC | $13.64 | 2023 | |
| Avanos Medical | $13.23 | 2022 | |
| Fidia Pharma USA INC. | $9.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.